EUVIMEDEUVIMED entdecken
Crossref

Leveraging a Multienzymes‐Mimicking Nanozyme to Overcome CDK4/6 Inhibitor Resistance and Achieve Drug Repurposing in Oesophageal Squamous Cell Carcinoma

Peilin Wu, Ling Lan, Zihan Li, Imran Shakir, Jin Zhou, Yongchao Yao, Binwu Ying, Juan Zhou, Xuping Sun iD, Yi Li, Fengming Luo

Small · 2026-05 · 22 (27)

DOI: 10.1002/smll.202514464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 08.04.2026. Verfasst von Peilin Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine/Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Drug Resistance, Neoplasm, Esophageal Squamous Cell Carcinoma. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Natural Science Foundation of China, National Key Research and Development Program of China, Sichuan Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitors, approved as checkpoint blockers for breast cancer therapy, have recently been investigated for oesophageal squamous cell carcinoma (OSCC), as it frequently harbors genetic alterations in cell cycle regulators. However, a phase II clinical trial showed no objective responses in OSCC, underscoring the critical challenge of drug resistance. Our findings reveal that the CDK4/6 inhibitors induce pan‐ERBB pathway activation and glutathione peroxidase 4 (GPX4) overexpression, which promote cellular metabolism and reduce sensitivity to apoptosis and ferroptosis. Together with these findings, we developed a CDK4/6 inhibitor‐loaded nano‐palladium supported single‐layer CoAl layered double hydroxide (Pd/s‐CALDH@Palbo) nanozyme. Pd/s‐CALDH@Palbo exhibits multienzymes‐mimicking activity and is capable of generating reactive oxygen species to synergize with CDK4/6 blockade. A series of in vitro and in vivo studies demonstrate that Pd/s‐CALDH@Palbo suppresses pan‐ERBB pathway activation and GPX4 overexpression, reduces cellular metabolism, and triggers apoptosis and ferroptosis, thereby effectively overcoming CDK4/6 inhibitor resistance and demonstrating potent antitumor efficacy in OSCC. Overall, our work presents a nanozyme‐mediated drug repurposing paradigm, with potential applications in precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Drug Resistance, NeoplasmEsophageal Squamous Cell CarcinomaDrug RepositioningEsophageal NeoplasmsProtein Kinase InhibitorsHumansCell Line, TumorAnimalsApoptosis

Stichwörter der Autor:innen

CDK4/6 inhibitordrug repurposingdrug resistancenanozymeoesophageal cancer

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsCDK4 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine/Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Physics, Faculty of Science, Islamic University of Madinah, Madinah, Saudi Arabia.
  • Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • College of Chemistry Chemical Engineering and Materials Science, Shandong Normal University, Jinan, Shandong, China.

ORCID-Profile: Xuping Sun

Förderung

  • Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Sichuan Science and Technology Program
  • Key Research and Development Science and Technology Program Project for High-Quality Development 2024 of The First People's Hospital of Zigong City
  • National Natural Science Foundation of China

Zitieren

APA

Wu, P., Lan, L., Li, Z., Shakir, I., Zhou, J., Yao, Y., Ying, B., Zhou, J., Sun, X., Li, Y., & Luo, F. (2026). Leveraging a Multienzymes‐Mimicking Nanozyme to Overcome CDK4/6 Inhibitor Resistance and Achieve Drug Repurposing in Oesophageal Squamous Cell Carcinoma. Small, 22(27). https://doi.org/10.1002/smll.202514464

Vancouver

Wu P, Lan L, Li Z, Shakir I, Zhou J, Yao Y, et al. Leveraging a Multienzymes‐Mimicking Nanozyme to Overcome CDK4/6 Inhibitor Resistance and Achieve Drug Repurposing in Oesophageal Squamous Cell Carcinoma. Small. 2026;22(27). doi:10.1002/smll.202514464

BibTeX
@article{Wu2026,
  author = {Wu, Peilin and Lan, Ling and Li, Zihan and Shakir, Imran and Zhou, Jin and Yao, Yongchao and Ying, Binwu and Zhou, Juan and Sun, Xuping and Li, Yi and Luo, Fengming},
  title = {Leveraging a Multienzymes‐Mimicking Nanozyme to Overcome CDK4/6 Inhibitor Resistance and Achieve Drug Repurposing in Oesophageal Squamous Cell Carcinoma},
  journal = {Small},
  year = {2026},
  volume = {22},
  number = {27},
  doi = {10.1002/smll.202514464}
}
Kostenlos starten →